NEW BRUNSWICK, N.J. — Johnson & Johnson announced Tuesday that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for
NEW BRUNSWICK, N.J. — Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others
NEW YORK — According to published reports, Walmart, CVS and Rite Aid are removing all 22-ounce bottles of Johnson & Johnson’s Baby Powder from their stores, following last week’s recall of one lot of the product due to possible asbestos contamination. J&J said last week it was recalling one lot, or 33K bottles, of baby
BRUNSWICK, N.J. — For the first time in over ten years, Johnson & Johnson Consumer is introducing the first new form of Children’s Tylenol with the release of Children’s Tylenol Dissolve Packs. The new product is the only pediatric acetaminophen offered in an orally dissolving granular form. The company said that its consumer research informed
NEW BRUNSWICK, N.J. – Johnson & Johnson and its Janssen Pharmaceutical Cos. announced they will appeal the $572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma’s lawsuit against opioid manufacturers. The company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with
NEW BRUNSWICK, N.J. – Johnson & Johnson announced the completion of the acquisition of Ci:z Holdings Co. for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share. Johnson & Johnson plans
NEW BRUNSWICK, N.J. — Johnson & Johnson will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13th, at The Phoenician in Scottsdale, AZ. Scott White, group chairman, North America Pharmaceuticals will represent the company in a session scheduled at 8:35 a.m. (MST). This webcast will be available to investors and other interested
NEW YORK —Parents want to feel good about what they put on their baby’s skin — and so does Johnson’s Baby. That’s why the brand is disclosing 100% of the ingredients in its found in its baby products—including those found in fragrances. Fragrance has long been considered a trade secret, but Johnson’s recognizes that today’s
SKILLMAN, N.J. — Johnson & Johnson Consumer Inc. announced that it has entered into a definitive agreement to acquire Zarbee’s, Inc., a privately held company that is a leader in naturally-based healthcare products. The acquisition will include the full line of Zarbee’s Naturals products for children and adults. Financial terms of the transaction were not disclosed.
DEERFIELD, Ill. — Walgreens introduced an exclusive skincare analysis tool called SkinID on Walgreens.com to evaluate each customer’s skincare needs and build a personalized, three-step daily routine that will help banish breakouts. The cleansing, treatment and moisturizing products recommended are selected from Walgreens vast products across a variety of brands utilizing Johnson & Johnson Consumer
JACKSONVILLE, Fla. — Johnson & Johnson Vision announced ACUVUE OASYS with Transitions Light Intelligent Technology, a first of its kind contact lens that provides wearers with vision correction and a dynamic photochromic filter that helps to continuously balance the amount of light entering the eye. These contact lenses are said to quickly and seamlessly adjust
NEW BRUNSWICK, N.J. — Dominic Caruso, executive vice president and chief financial officer at Johnson & Johnson, is slated to retire this fall and be succeeded by Joseph Wolk. The company said late Tuesday that Caruso, who plans to retire in September, has served as Johnson & Johnson CFO longer than anyone in its 132- year
NEW BRUNSWICK, N.J. — Johnson & Johnson has reached an agreement to acquire Switzerland-based biopharmaceutical company Actelion Ltd. for $30 billion in cash. J&J said Actelion’s differentiated, innovative products for pulmonary arterial hypertension (PAH) are highly complementary to the portfolio of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company also noted that the
WASHINGTON — The Pharmaceutical Research and Manufacturers of America has named Joaquin Duato, worldwide chairman of pharmaceuticals as Johnson & Johnson, as chairman of the PhRMA board of directors. Duato previously was chairman-elect on the PhRMA board and succeeds George Scangos, who has stepped down as chief executive officer of Biogen. “In the words of
